THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the third quarter and the nine months ended September 30, 2025. “We are pleased with our third quarter results, which met our stated guidance and reflect the disciplined execution of our teams as we continue to deliver on our strategic objectives,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes. “During the quarter, we closed 1,107 homes, including 42 currently and previously leased homes, generated $396.6 million in revenue, and delivered gross and adjusted gross margins within our guidance range. Our teams remained focused on driving leads, managing inventory, and executing on sales initiatives that directly contributed an 8.1% year-over-year increase and 43.9% sequential increase in...

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateSharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-synCash resources of CHF 108.5 million as of September 30, 2025, provide funding to the end of Q3 2027 excluding any income from potential milestones Peer-reviewed papers covering groundbreaking results including clinical data on ACI-35.030 (JNJ-64042056) published in eBioMedicine and preclinical data on first-in-class PET tracers for imaging TDP-43 pathology published in Nature Communications IND/CTA filing for small molecule NLRP3 inhibitor ACI-19764 and the start of IND-enabling studies for Morphomer-Tau aggregation inhibitor both expected by year-endLausanne, Switzerland, November 4, 2025...

Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights:Initiated U.S. commercial launch of the CGuard Prime carotid stent system Completed over 100 U.S. carotid procedures across leading hospitals Strengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical Officer Appointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMDMarvin Slosman, CEO of InspireMD, commented: “Our business demonstrated...

MONACO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the third quarter and nine-month period ended September 30, 2025. Discontinued operations as a result of Costamare Bulkers Holdings Limited Spin–Off The financial results for the nine-month period ended September 30, 2025, reflect the spin-off of Costamare’s dry bulk business (consisting of Costamare’s dry bulk owned fleet and its dry bulk operating platform, Costamare Bulkers Inc. (“CBI”)) into a standalone public company, which was completed on May 6, 2025. Accordingly, the results of the dry bulk business are presented as discontinued operations for all periods shown. For the nine-month period ended September 30, 2025, the results of discontinued operations include the dry bulk...

Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restricted cash MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world,...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization of 555 subjects Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027 Registrational HELIOS program for AXPAXLI in NPDR expected to begin imminently using a novel primary endpoint Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining...

Q3 revenue increased 28% year-over-year to a record $181 million, driven by robust marketplace growth. Q3 marketplace revenue growth accelerated to 31% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers. Q3 gross profit increased 29% year-over-year to a record $72.0 million, driven by record marketplace gross margin of 35.7%. Q3 Adjusted EBITDA improved $6.8 million year-over-year to Adjusted EBITDA of $6.1 million driven by expanding marketplace gross margin and strong operating expense leverage. Strong operating results were driven by consistent execution across growth initiatives: expanding buyer and supplier networks, driving deeper enterprise engagement, further expanding the marketplace platform, growing internationally, and enhancing supplier services.NORTH BETHESDA, Md., Nov. 04,...

Continued strong financial results and cash generation Revenue, up 4% versus prior year, driven by durable recurring monthly revenue Year-to-date GAAP Operating Cash Flow up 6%, Adjusted Free Cash Flow (including swaps) up 36% Returned $746 million to shareholders year to date through share repurchases and dividends On track to achieve full-year 2025 guidance metrics BOCA RATON, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT) today reported results for the third quarter of 2025. Financial highlights for the third quarter are below with variances on a year-over-year basis unless otherwise noted. Results of the former commercial and solar businesses are presented as discontinued operations, except for cash flow measures.Total revenue increased 4% to $1.3 billion and end-of-period recurring monthly revenue (RMR) increased...

Achieves Record Quarterly Aggregates Revenues, Profitability and Margin Establishes Record Quarterly Revenues and Third Quarter Gross Profit in Specialties Business Raises Full-Year 2025 Guidance RALEIGH, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE: MLM) (Martin Marietta or the Company), a leading national supplier of aggregates and heavy building materials, today reported results for the third quarter ended September 30, 2025. Third-Quarter Highlights(Financial highlights are for continuing operations, unless otherwise noted)  Quarter Ended September 30,(In millions, except per share and per ton) 2025   2024   % ChangeRevenues1 $1,846   $1,642   12%Gross profit $611   $513   19%Earnings from operations $505   $406   24%Net earnings from continuing operations attributable to Martin...

HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Natural Resource Partners L.P. (NYSE:NRP) today reported third quarter 2025 results as follows:  For the Three MonthsEnded   Last Twelve MonthsEnded(In thousands) (Unaudited) September 30, 2025Net income $ 30,905     $ 148,141  Operating cash flow   41,095       187,318  Free cash flow(1)   41,823       190,146           (1) See “Non-GAAP Financial Measures” and reconciliation tables at the end of this release.     Highlights:Generated $41.8 million of free cash flow in the third quarter of 2025 Paid second quarter 2025 common unit distribution of $0.75 per unit Declares third quarter 2025 common unit distribution of $0.75 per unit“NRP continues to generate substantial free cash flow despite ongoing depressed market conditions for all...